IgA NEPHROPATHY INCIDENCE

Primary IgA nephropathy is a chronic autoimmune disease4-6

IgA nephropathy is the most common cause of the primary glomerular diseases that can lead to
end-stage renal disease (ESRD)
.6
globe pointers

~2.5/
100,000

individuals per year suffer from IgAN worldwide7

IgA NEPHROPATHY PROGRESSION

Half of patients with IgA nephropathy may progress to ESRD within 20 years2,3

*In a retrospective analysis of patients with IgA nephropathy referred to the Center for Glomerular Diseases at Columbia University Medical Center from 1980 to 2010. Only patients with a biopsy-proven diagnosis and ≥6 months of follow-up were included in outcome analysis (n=126).8

In a 10-year, long-term follow-up of a cohort of patients (n=149) from the multicenter, open-label, randomized, controlled STOP-IgAN trial. This study represents one of the longest and most rigorously designed IgA nephropathy studies with the highest evidence currently available.9

In a study of adults from central and eastern Kentucky who were diagnosed with IgA nephropathy (N=251) by renal biopsy between January 1, 1976 and December 31, 2005, which used the National Death Index and United States Renal Data System to establish date of death and date of progression to ESRD.2

IgA nephropathy is often asymptomatic in early stages. Patients may go undiagnosed until a decline in kidney function has already occurred6,10

IgA NEPHROPATHY HIDDEN COSTS

IgA nephropathy progression comes at a high cost.11

money cost
According to the American Journal of Managed Care, mean annual costs for patients with ESRD were $121,948 for commercial groups and $87,339 for Medicare groups12
personal cost
Progressive IgA nephropathy can also have a deep impact on emotional and psychosocial aspects, as well as a patient’s ability to perform physical activities6
life cost

In the American Journal of Kidney Diseases, the mortality rate in patients with moderate- or high-risk IgAN was twice that of the general population in a large cohort study (N=665) followed for a mean duration of 11.8 years (range: 0.0 to 20.8 years)13

See the true impact of IgA nephropathy

A patient with lgA nephropathy discusses the challenges he faces, with commentary from University of Leicester Professor Jonathan Barratt.

IgA=immunoglobulin A; IgAN=immunoglobulin A nephropathy; MOD=mechanism of disease.

References

1. Barratt J, Rovin BH, Cattran D, et al. Kidney Int Rep. 2020;5(20):1620-1624. doi:10.1016/j.ekir.2020.08.009

2. Hastings MC, Bursac Z, Julian BA, et al. Kidney Int Rep. 2017;3(1):99-104. doi:10.1016/j.ekir.2017.08.008

3. Schena FP. Am J Med. 1990;89(2):209-215. doi:10.1016/0002-9343(90)90300-3

4. Barratt J, Feehally J. Semin Nephrol. 2011;31(4):349-360. doi:10.1016/j.semnephrol.2011.06.006

5. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int. 2012;2(suppl 2):259-274.

6. IgA Nephropathy Foundation of America, Inc. The Voice of the Patient: Externally Led Patient-Focused Drug Development Meeting on IgA Nephropathy. https://nkf.egnyte.com/dl/aHGCS6tPNM/?. Accessed August 18, 2021.

7. Penfold RS, Prendecki M, McAdoo S, Tam FWK. Int J Nephrol Renovasc Dis. 2018;11:137-148. doi:10.2147/IJNRD.S129227

8. Arroyo AH, Bomback AS, Butler B, et al. Clin Nephrol. 2015;84(3):145-155. doi:10.5414/CN108556

9.Rauen T, Wied S, Fitzner C, et al; for the STOP-IgAN Investigators. Kidney Int Supp.2020;98(4):1044-1052. doi:10.1016/j.kint.2020.04.046

10. Lafayette RA, Kelepouris E. Am J Nephrol. 2018;47(suppl 1):43-52. doi:10.1159/000481636

11. United States Renal Data System (USRDS). 2018 USRDS Annual Data Report. Vol 2. 2018; chap 9. Accessed April 7, 2021. https://usrds.org/media/1734/v2_c09_esrd_costs_18_usrds.pdf.

12. Golestaneh L, Alvarez PJ, Reaven N, et al. Am J Manag Care. 2017;23(10 Suppl):S163-S172.

13. Knoop T, Vikse BE, Svarstad E, Leh S, Reisæter AV, Bjørneklett R. Am J Kidney Dis. 2013;62(5):883-890. doi:10.1053/j.ajkd.2013.04.019

14. Ponticelli C, Glassock RJ. Clin J Am Soc Nephrol. 2010;5(12):2363-2372. doi:10.2215/CJN.06720810

15. Ponticelli C, Traversi L, Banfi G. Pediatr Transplantat. 2004:8(4):334-338. doi:10.1111/j.1399-3046.2004.00177.x

16. He J-W, Zhou X-J, Lv J-C, Zhang H. Theranostics. 2020;10(25):11462-11478. doi:10.7150/thno.49778

17. Cheung CK, Barratt J. 2020. Accessed April 7, 2021. https://www.uptodate.com/contents/pathogenesis-of-iga-nephropathy?search=pathogenesis%20of%20iga%20nephropathy&source=search_result&selectedTitle=1~126&usage_type=default&display_rank=1.

18. Reinholdt J, Husby S. In: Morteau O, ed. Oral Tolerance: The Response of the Intestinal Mucosa to Dietary Antigens. Landes Bioscience; 2003.

19. Floege J. J Am Soc Nephrol. 2019;30(7):1139-1141. doi:10.1681/ASN.2019040373

20. Wehbi B, Oblet C, Boyer F, et al. J Am Soc Nephrol. 2019;30(7):1238-1249. doi:10.1681/ASN.2018111089

21. Thompson A, Carroll K, Inker LA, et al. Clin J Am Soc Nephrol. 2019;14(3):469-481. doi:10.2215/CJN.08600718

22. Ibrahim A, Garg AX, Knoll GA, Akbari A, White CA. Am J Transplant. 2013;13(3):708-713. doi:10.1111/ajt.12050

23. Levey AS, Gansevoort RT, Coresh J, et al. Am J Kidney Dis. 2020;75(1):84-104. doi:10.1053/j.ajkd.2019.06.009

24. Goto M, Wakai K, Kawamura T, Ando M, Endoh M, Tomino Y. Nephrol Dial Transplant. 2009;24(10):3068-3074. doi:10.1093/ndt/gfp273

25. Brantsma AH, Atthobari J, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT. J Am Soc Nephrol. 2007;18(2):637-645. doi:10.1681/ASN.2006070738